vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.3× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -13.6%, a 30.6% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -5.3%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $96.0M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs -3.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
JAZZ vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.5B |
| Net Profit | $203.5M | $-205.0M |
| Gross Margin | — | 49.2% |
| Operating Margin | 21.2% | -9.8% |
| Net Margin | 17.0% | -13.6% |
| Revenue YoY | 10.1% | -5.3% |
| Net Profit YoY | 6.5% | -288.1% |
| EPS (diluted) | $3.34 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | $897.8M | $1.5B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $1.1B | $1.6B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $902.0M | $1.6B |
| Q4 25 | $203.5M | $-205.0M | ||
| Q3 25 | $251.4M | $160.0M | ||
| Q2 25 | $-718.5M | $145.0M | ||
| Q1 25 | $-92.5M | $87.0M | ||
| Q4 24 | $191.1M | $109.0M | ||
| Q3 24 | $215.1M | $359.0M | ||
| Q2 24 | $168.6M | $195.0M | ||
| Q1 24 | $-14.6M | $201.0M |
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | 21.2% | -9.8% | ||
| Q3 25 | 5.1% | 15.2% | ||
| Q2 25 | -65.6% | 14.4% | ||
| Q1 25 | -6.2% | 6.7% | ||
| Q4 24 | 17.5% | 8.1% | ||
| Q3 24 | 24.7% | 13.1% | ||
| Q2 24 | 19.5% | 14.6% | ||
| Q1 24 | 7.3% | 14.5% |
| Q4 25 | 17.0% | -13.6% | ||
| Q3 25 | 22.3% | 10.0% | ||
| Q2 25 | -68.7% | 9.1% | ||
| Q1 25 | -10.3% | 5.8% | ||
| Q4 24 | 17.6% | 6.8% | ||
| Q3 24 | 20.4% | 22.7% | ||
| Q2 24 | 16.5% | 12.1% | ||
| Q1 24 | -1.6% | 12.4% |
| Q4 25 | $3.34 | $-0.78 | ||
| Q3 25 | $4.08 | $0.61 | ||
| Q2 25 | $-11.74 | $0.56 | ||
| Q1 25 | $-1.52 | $0.33 | ||
| Q4 24 | $2.97 | $0.42 | ||
| Q3 24 | $3.42 | $1.38 | ||
| Q2 24 | $2.49 | $0.75 | ||
| Q1 24 | $-0.23 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $574.0M |
| Total DebtLower is stronger | $5.4B | $8.6B |
| Stockholders' EquityBook value | $4.3B | $752.0M |
| Total Assets | $11.7B | $12.9B |
| Debt / EquityLower = less leverage | 1.24× | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $574.0M | ||
| Q3 25 | $1.3B | $672.0M | ||
| Q2 25 | $1.2B | $599.0M | ||
| Q1 25 | $1.9B | $547.0M | ||
| Q4 24 | $2.4B | $675.0M | ||
| Q3 24 | $2.2B | $763.0M | ||
| Q2 24 | $1.4B | $704.0M | ||
| Q1 24 | $1.4B | $575.0M |
| Q4 25 | $5.4B | $8.6B | ||
| Q3 25 | $5.4B | $8.8B | ||
| Q2 25 | $5.4B | $8.9B | ||
| Q1 25 | $5.4B | $9.0B | ||
| Q4 24 | $6.1B | $8.9B | ||
| Q3 24 | $6.1B | $8.7B | ||
| Q2 24 | $5.7B | $8.7B | ||
| Q1 24 | $5.7B | $8.7B |
| Q4 25 | $4.3B | $752.0M | ||
| Q3 25 | $4.0B | $906.0M | ||
| Q2 25 | $3.7B | $733.0M | ||
| Q1 25 | $4.2B | $542.0M | ||
| Q4 24 | $4.1B | $472.0M | ||
| Q3 24 | $4.2B | $493.0M | ||
| Q2 24 | $3.8B | $144.0M | ||
| Q1 24 | $3.7B | $48.0M |
| Q4 25 | $11.7B | $12.9B | ||
| Q3 25 | $11.4B | $13.6B | ||
| Q2 25 | $10.9B | $13.5B | ||
| Q1 25 | $11.5B | $13.2B | ||
| Q4 24 | $12.0B | $13.1B | ||
| Q3 24 | $12.3B | $12.8B | ||
| Q2 24 | $11.4B | $12.2B | ||
| Q1 24 | $11.3B | $11.9B |
| Q4 25 | 1.24× | 11.49× | ||
| Q3 25 | 1.35× | 9.74× | ||
| Q2 25 | 1.45× | 12.14× | ||
| Q1 25 | 1.29× | 16.52× | ||
| Q4 24 | 1.49× | 18.81× | ||
| Q3 24 | 1.47× | 17.75× | ||
| Q2 24 | 1.52× | 60.11× | ||
| Q1 24 | 1.54× | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $141.0M |
| Free Cash FlowOCF − Capex | $345.8M | $96.0M |
| FCF MarginFCF / Revenue | 28.9% | 6.4% |
| Capex IntensityCapex / Revenue | 1.4% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $141.0M | ||
| Q3 25 | $474.6M | $264.0M | ||
| Q2 25 | $88.9M | $220.0M | ||
| Q1 25 | $429.8M | $75.0M | ||
| Q4 24 | $398.6M | $390.0M | ||
| Q3 24 | $398.7M | $141.0M | ||
| Q2 24 | $331.4M | $332.0M | ||
| Q1 24 | $267.2M | $76.0M |
| Q4 25 | $345.8M | $96.0M | ||
| Q3 25 | $459.4M | $218.0M | ||
| Q2 25 | $75.9M | $181.0M | ||
| Q1 25 | $415.9M | $43.0M | ||
| Q4 24 | $385.3M | $335.0M | ||
| Q3 24 | $388.0M | $99.0M | ||
| Q2 24 | $324.3M | $300.0M | ||
| Q1 24 | $260.3M | $30.0M |
| Q4 25 | 28.9% | 6.4% | ||
| Q3 25 | 40.8% | 13.6% | ||
| Q2 25 | 7.3% | 11.4% | ||
| Q1 25 | 46.3% | 2.8% | ||
| Q4 24 | 35.4% | 21.0% | ||
| Q3 24 | 36.8% | 6.3% | ||
| Q2 24 | 31.7% | 18.7% | ||
| Q1 24 | 28.9% | 1.8% |
| Q4 25 | 1.4% | 3.0% | ||
| Q3 25 | 1.3% | 2.9% | ||
| Q2 25 | 1.2% | 2.4% | ||
| Q1 25 | 1.5% | 2.1% | ||
| Q4 24 | 1.2% | 3.5% | ||
| Q3 24 | 1.0% | 2.7% | ||
| Q2 24 | 0.7% | 2.0% | ||
| Q1 24 | 0.8% | 2.8% |
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | 1.65× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | 2.09× | 3.58× | ||
| Q3 24 | 1.85× | 0.39× | ||
| Q2 24 | 1.97× | 1.70× | ||
| Q1 24 | — | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
OGN
Segment breakdown not available.
